For instance, it is exciting to find that enzastaurin and ruboxistaurin, two compounds in clinical trials, can decrease tau in our human neurons; this raises the possibility of rapidly repurposing these or related drugs for tauopathy therapy. Here, MAPT is linked to tauopathy.